SCHEMBL16673174

SCHEMBL16673174

C[C@H](S)NC(c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNN4 O15554 5/20 0.50
KIF11 P52732 1/20 0.38
CYP2D6 P10635 2/20 0.35
CYP1A2 P05177 1/20 0.35
MAPK1 P28482 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
CACNA1F O60840 1/20 0.34
CHRM2 P08172 1/20 0.34
CHRM1 P11229 1/20 0.34
ADRA2B P18089 1/20 0.34
CHRM3 P20309 1/20 0.34
ADRA1A P35348 1/20 0.34
HRH1 P35367 1/20 0.34
OPRK1 P41145 1/20 0.34
CACNA1D Q01668 1/20 0.34
SLC6A3 Q01959 1/20 0.34
KCNH2 Q12809 1/20 0.34
CACNA1S Q13698 1/20 0.34
CACNA1C Q13936 1/20 0.34
SCN5A Q14524 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9025613 1.00 KCNN4 (0.50) KCNN4KIF11CYP2D6CYP1A2MAPK1
SCHEMBL2160833 0.77 KCNN4 (0.50) KCNN4KIF11CYP2D6CYP1A2MAPK1
SCHEMBL4495324 0.77 KCNN4 (0.50) KCNN4KIF11CYP2D6CYP1A2CHRM2
SCHEMBL10675289 0.77 KCNN4 (0.50) KCNN4KIF11CYP2D6CYP1A2MAPK1
SCHEMBL2771122 0.75 CYP1A2 (0.40) KCNN4KIF11CYP2D6CYP1A2ALDH1A1
SCHEMBL19381442 0.74 KCNN4 (0.46) KCNN4KIF11CYP2D6CYP1A2TDP1
SCHEMBL16609226 0.74 KCNN4 (0.52) KCNN4KIF11TDP1CACNA1FCHRM2
SCHEMBL6566499 0.74 KCNN4 (0.52) KCNN4KIF11TDP1CACNA1FCHRM2
SCHEMBL7556522 0.74 KCNN4 (0.46) KCNN4KIF11CYP2D6CYP1A2MAPK1
SCHEMBL2552806 0.72 KCNN4 (0.45) KCNN4KIF11CYP2D6CYP1A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105764909-B stable pantetheine derivatives for the treatment of pantothenate kinase-associated neurodegeneration (PKAN) and methods for synthesizing such compounds 阿西耶斯生物公司 2019-12-06 CN disclosed
EP-3066106-B1 STABLE PANTETHEINE DERIVATIVES FOR THE TREATMENT OF PANTOTHENATE KINASE ASSOCIATED NEURODEGENERATION (PKAN) AND METHODS FOR THE SYNTHESIS OF SUCH COMPOUNDS ACIES BIO D O O (SI) 2019-08-14 EP disclosed
US-9963472-B2 Stable pantetheine derivatives for the treatment of pantothenate kinase associated neurodegeneration (PKAN) and methods for the synthesis of such compounds ACIES BIO D.O.O. (SI) 2018-05-08 US disclosed
US-20180118767-A1 STABLE PANTETHEINE DERIVATIVES FOR THE TREATMENT OF PANTOTHENATE KINASE ASSOCIATED NEURODEGENERATION (PKAN) AND METHODS FOR THE SYNTHESIS OF SUCH COMPOUNDS COMET THERAPEUTICS B.V. (NL) 2018-05-03 US disclosed
US-20160297840-A1 STABLE PANTETHEINE DERIVATIVES FOR THE TREATMENT OF PANTOTHENATE KINASE ASSOCIATED NEURODEGENERATION (PKAN) AND METHODS FOR THE SYNTHESIS OF SUCH COMPOUNDS VECTIVBIO COMET AG, F/K/A COMET THERAPEUTICS, INC. (CH) 2016-10-13 US disclosed
EP-3066106-A1 STABLE PANTETHEINE DERIVATIVES FOR THE TREATMENT OF PANTOTHENATE KINASE ASSOCIATED NEURODEGENERATION (PKAN) AND METHODS FOR THE SYNTHESIS OF SUCH COMPOUNDS Acies Bio d.o.o. (SI) 2016-09-14 EP disclosed
WO-2015063177-A1 STABLE PANTETHEINE DERIVATIVES FOR THE TREATMENT OF PANTOTHENATE KINASE ASSOCIATED NEURODEGENERATION (PKAN) AND METHODS FOR THE SYNTHESIS OF SUCH COMPOUNDS ACIES BIO D.O.O. (SI) 2015-05-07 WO disclosed
EP-2868662-A1 Stable pantetheine derivatives for the treatment of pantothenate kinase associated neurodegeneration (pkan) and methods for the synthesis of such compounds Acies Bio d.o.o. (SI) 2015-05-06 EP disclosed
US-20140107135-A1 PYRIMIDINONE INHIBITORS OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 AUSPEX PHARMACEUTICALS, INC. (US) 2014-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180118767-A1 STABLE PANTETHEINE DERIVATIVES FOR THE TREATMENT OF PANTOTHENATE KINASE ASSOCIATED NEURODEGENERATION (PKAN) AND METHODS FOR THE SYNTHESIS OF SUCH COMPOUNDS PANK3, PANK1, PANK2 KCNN4 2577/4885KIF11 2552/4885CYP2D6 3979/4885
US-20140107135-A1 PYRIMIDINONE INHIBITORS OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 PLA2G1B, PLA2G4A, PLA2G4B KCNN4 4626/4885KIF11 4738/4885CYP2D6 1842/4885
US-20160297840-A1 STABLE PANTETHEINE DERIVATIVES FOR THE TREATMENT OF PANTOTHENATE KINASE ASSOCIATED NEURODEGENERATION (PKAN) AND METHODS FOR THE SYNTHESIS OF SUCH COMPOUNDS PANK3, PANK1, PANK2 KCNN4 2577/4885KIF11 2552/4885CYP2D6 3979/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.